Test Price
2,800 AED✅ Home Collection Available
SMN1 Gene Sequencing (SMA Type 3) – Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل تسلسل جين SMN1 لمرض ضمور العضلات الشوكي النوع 3 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
▼ Executive Summary & UAE Trust Guarantee
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection using ISO Certified Cold-Chain Transport & VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation with a DHA-licensed neurologist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
ملخص تنفيذي: يضمن هذا التحليل دقة تشخيصية بنسبة 99.9% تحت إجراءات معيار ISO 9001:2015، مع خدمة سحب منزلي متميزة وإرشادات طبية بعد الفحص للالتزام التام بقوانين دولة الإمارات العربية المتحدة.
Overview
The SMN1 Gene Sequencing test utilizes Next‑Generation Sequencing (NGS) with integrated dosage analysis to detect copy number variations (exon 7/8 deletions or duplications) and point mutations, confirming a clinical diagnosis of Spinal Muscular Atrophy Type 3 (Kugelberg‑Welander disease) and guiding carrier screening and family planning.
يستخدم تحليل تسلسل جين SMN1 تقنية التسلسل الجيني المتقدم للكشف عن حذف الإكسونات 7 و8 وتأكيد تشخيص ضمور العضلات الشوكي النوع 3، مع إمكانية تحديد حاملي المرض في العائلة.
| Feature | Our SMN1 NGS Test | Closest Alternative (Standard MLPA Only) |
|---|---|---|
| Precision & Scope | Simultaneous detection of exon 7/8 copy number, point mutations, and SMN2 modifier copy number | Only exon 7/8 deletion/duplication – misses 5–10% of cases with intragenic mutations |
| Methodology | High‑coverage NGS with dosage analysis (LC‑MS/MS‑compatible data pipeline) | MLPA with limited point‑mutation analysis |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks |
| Regulatory & Accreditation | ISO 9001:2015, UAE PDPL, Federal Decree‑Law No. 41 of 2024 | Often limited to basic CAP accreditation |
| Price | 2800 AED | 2500–3200 AED (variable, less comprehensive) |
Physician Insight & Safety Protocol
“As a clinical neurologist, I emphasize that this genetic test provides definitive molecular confirmation, but the diagnosis of SMA type 3 must always be correlated with detailed neurological examination, electromyography, and natural history. Please remember that a negative result does not exclude other motor neuron disorders, and all findings should be integrated by a specialist before initiating therapy. Tele‑counselling is available for results interpretation.”
— Dr. Prabhakar Reddy, DHA License: 61713011
⚠️ Important Safety & Exclusion Information
Medication Warning: Do not discontinue prescribed medication without consulting your doctor. This test does not replace ongoing neurological care.
Exclusion Criteria: This test is not indicated for asymptomatic individuals without a family history of SMA unless as part of a formal genetic counseling programme. It is not designed for forensic, paternity, or prenatal diagnosis without prior specialist referral.
Emergency Red Flags: If during the testing process you experience sudden muscle weakness, respiratory difficulty, or swallowing problems, seek immediate medical attention at the nearest emergency department. These signs may indicate unrelated acute neuromuscular compromise.
This service strictly complies with Federal Decree‑Law No. 41 of 2024 (Art. 87) on genetic data, the 2026 CDS Law for minors, and the UAE Personal Data Protection Law (PDPL). ISO 9001:2015 Certificate: INT/EGQ/2509DA/3139.
Patient FAQ & Clinical Guidance
Q1: What is the diagnostic accuracy of the SMN1 NGS test for SMA type 3?
The test achieves 99.9% diagnostic sensitivity by simultaneously detecting exon 7/8 deletions, point mutations, and SMN2 copy number modifiers using high-coverage NGS. This comprehensive approach minimises false negatives and clarifies prognosis by assessing the SMN2 gene dosage, which influences disease severity. All results are reviewed by a DHA‑licensed clinical geneticist before release.
تبلغ الحساسية التشخيصية للتحليل 99.9% من خلال الكشف المتزامن عن حذف الإكسونات 7 و8 والطفرات النقطية ونسخ جين SMN2، مما يضمن تحديداً دقيقاً للنمط الجيني وتقديراً لشدة المرض.
Q2: How long does it take to receive my results, and what does the home collection involve?
You will receive your comprehensive report within 3 to 4 weeks after a premium hospital‑grade home blood draw performed by a certified phlebotomist between 8 AM and 11 PM, using ISO‑certified cold‑chain transport. A pre‑test genetic counselling session ensures proper family pedigree documentation; a single tube of whole blood, extracted DNA, or one drop on an FTA card is accepted.
تستلم تقريرك الشامل خلال 3 إلى 4 أسابيع بعد سحب عينة الدم منزلياً عبر ممرض معتمد ضمن ساعات 8 صباحاً – 11 مساءً مع نقل مبرد معتمد من ISO.
Q3: Is this test covered by insurance and are there legal requirements in the UAE?
We offer direct insurance billing verification via WhatsApp; this genetic strictly adheres to Federal Decree‑Law No. 41 of 2024 and mandates explicit consent for genetic data processing under UAE PDPL, including a tele‑counselling session. The laboratory holds ISO 9001:2015 accreditation (Cert: INT/EGQ/2509DA/3139) and DHA facility license 9834453.
نقدم توثيقاً مباشراً للتأمين الصحي عبر واتساب، ويلتزم الفحص بالقانون الاتحادي رقم 41 لسنة 2024 وقانون حماية البيانات الشخصية ويتطلب موافقة صريحة مع جلسة استشارة وراثية هاتفية.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians